---
title: "Vivalyx: Developer of Omnisol, an investigational perfusion solution for preserving donor organs"
url: https://emrr.uz/vivalyx
language: en
updated: 2026-11-18T13:51:01Z
source: emrr (https://emrr.uz)
---

# Vivalyx

Developer of Omnisol, an investigational perfusion solution for preserving donor organs

[vivalyx.com](https://www.vivalyx.com/)

- **Industry**: Biotech, MedTech
- **Founded**: 2022
- **Based in**: Germany

## Verified revenue: not connected yet

Is Vivalyx yours? Claim this page and connect Stripe, the App Store or Google Play: your MRR and growth show here, read straight from the source.

[Claim it if it’s yours](https://panel.emrr.uz/reserve/vivalyx)

## About

Vivalyx develops Omnisol, a blood-replacing perfusion solution designed to preserve and revitalise donor organs for transplantation. Omnisol is investigational and has entered first-in-human clinical use. The company is based in Aachen, Germany and is backed by Armenia-based Granatus Ventures.

## Team

- **Andreas Schumacher**, Co-founder and CEO (Founder)
- **Benedict Doorschodt**, Co-founder and CTO (Founder)
- **René Tolba**, Co-founder and CMO (Founder)
- **Christian Bleilevens**, Co-founder and CSO (Founder)
- **Malte Brettel**, Co-founder (Founder)
- **Marius Rosenberg**, Co-founder (Founder)

## Audience

Followers on social networks

- [LinkedIn vivalyx](https://www.linkedin.com/company/vivalyx/)

Profile data from Stanbase.

Updated 18 November 2026

[This page in Markdown](https://emrr.uz/vivalyx.md)

[Get your verified page](https://emrr.uz/): Connect Stripe, the App Store or Google Play in two minutes and get a page like this one. emrr reads every figure itself, so investors don’t have to take your word for it. Free while MRR is under $1,000.
